Search results for "clinical research"

showing 10 items of 474 documents

Plasma Arginine/Asymmetric Dimethylarginine Ratio and Incidence of Cardiovascular Events: A Case-Cohort Study.

2017

CONTEXT: Arginine, its methylated metabolites, and other metabolites related to the urea cycle have been independently associated with cardiovascular risk, but the potential causal meaning of these associations (positive for some metabolites and negative for others) remains elusive due to a lack of studies measuring metabolite changes over time. OBJECTIVE: To examine the association between baseline and 1-year concentrations of urea cycle metabolites and cardiovascular disease (CVD) in a case-cohort setting. DESIGN: A case-cohort study was nested within the Prevención con Dieta Mediterránea trial. We used liquid chromatography-tandem mass spectrometry to assess metabolite levels at baseline…

MaleOrnithineArginineEndocrinology Diabetes and MetabolismSistema cardiovascular -- MalaltiesClinical BiochemistryMyocardial Infarction030204 cardiovascular system & hematologyBiochemistryGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsTandem Mass SpectrometryProspective StudiesProspective cohort studyeducation.field_of_studyIncidenceHazard ratioMiddle AgedStrokeCardiovascular DiseasesFemalemedicine.medical_specialtyPopulation030209 endocrinology & metabolismContext (language use)Lower riskArginine03 medical and health sciencesInternal medicinemedicineHumanscardiovascular diseaseseducationClinical Research ArticlesDieta -- Mediterrània Regió de laAgedProportional Hazards Modelsomega-N-Methylargininebusiness.industryBiochemistry (medical)Case-control studyEndocrinologychemistryCase-Control StudiesMultivariate AnalysisCitrullinebusinessAsymmetric dimethylarginineChromatography Liquid
researchProduct

The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance : Evidence of validity

2014

BackgroundAn international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance.MethodsFourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web-platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T.ResultsThe agreement among tracers was relatively low…

MalePathologyDiagnostic criteriaEpidemiologyImage Processinggenetics [Alzheimer Disease]HippocampusFunctional LateralityImagingpathology [Alzheimer Disease]ddc:616.89methods [Magnetic Resonance Imaging]Computer-AssistedClinical trialsddc:150methods [Image Processing Computer-Assisted]ValidationImage Processing Computer-AssistedSegmentationHARPmedicine.diagnostic_testHealth PolicyOrgan SizeAlzheimer's diseaseMiddle Agedinstrumentation [Magnetic Resonance Imaging]Manual segmentationMagnetic Resonance ImagingPsychiatry and Mental healthMagnetic resonanceBiomedical ImagingManual segmentationFemalemethods [Neuroimaging]methods [Imaging Three-Dimensional]EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiativemedicine.medical_specialtyHippocampal volumetry; Magnetic resonance; Alzheimer's disease; Biomarkers; Diagnostic criteria; Enrichment; Clinical trials; Validation; Harmonized protocol; Standard operating procedures; Manual segmentationConcurrent validityClinical SciencesHarmonized protocolNeuroimagingArticleHippocampal volumetryCellular and Molecular NeuroscienceImaging Three-DimensionalDevelopmental NeuroscienceNeuroimagingClinical ResearchAlzheimer DiseasemedicineHumansddc:610AgedProtocol (science)ReproducibilityInternetbusiness.industryNeurosciencesReproducibility of ResultsMagnetic resonance imagingBrain DisordersStandard operating procedurespathology [Hippocampus]EnrichmentGeriatricsThree-DimensionalNeurology (clinical)Geriatrics and GerontologyAtrophyNuclear medicinebusinessBiomarkers
researchProduct

Immunopositivity for histone macroH2A1 isoforms marks steatosisassociated hepatocellular carcinoma.

2012

BackgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Prevention and risk reduction are important and the identification of specific biomarkers for early diagnosis of HCC represents an active field of research. Increasing evidence indicates that fat accumulation in the liver, defined as hepatosteatosis, is an independent and strong risk factor for developing an HCC. MacroH2A1, a histone protein generally associated with the repressed regions of chromosomes, is involved in hepatic lipid metabolism and is present in two alternative spliced isoforms, macroH2A1.1 and macroH2A1.2. These isoforms have been shown to predict lung and colon cancer recurrence but to ou…

MalePathologyMouseBiological Markers/metabolismEpidemiologyTumor Microenvironment/geneticsColorectal cancerGene ExpressionHepatocytes/metabolism/pathologyNonalcoholic SteatohepatitisHistonesFatty Liver/chemically induced/complications/genetics/metabolismMice0302 clinical medicineGastrointestinal CancersTumor MicroenvironmentPathologyProtein IsoformsDiethylnitrosamineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateMice KnockoutRegulation of gene expression0303 health sciencesMultidisciplinaryProtein Isoforms/genetics/metabolismbiologyLiver DiseasesPTEN Phosphohydrolase/deficiency/geneticshepatocellular carcinoma biomarker histone variant steatosis epigeneticsLiver NeoplasmsQFatty liverRHistone ModificationAnimal ModelsImmunohistochemistry3. Good healthHistoneOncology030220 oncology & carcinogenesisHepatocellular carcinomaMedicineEpigeneticsCarcinoma Hepatocellular/etiology/genetics/metabolism/pathologyResearch ArticleGene isoformmedicine.medical_specialtyCarcinoma HepatocellularHistologyClinical Research DesignScienceGastroenterology and HepatologyDiet High-Fat03 medical and health sciencesModel OrganismsDiagnostic MedicineGastrointestinal TumorsGeneticsCancer GeneticsCancer Detection and DiagnosisEarly DetectionmedicineAnimalsHumansAnimal Models of DiseaseObesityddc:612BiologyHistones/genetics/metabolismNutrition030304 developmental biologyCell NucleusCell Nucleus/genetics/metabolism/pathologyTumor microenvironmentbusiness.industryPTEN PhosphohydrolaseCancers and NeoplasmsHepatocellular Carcinomamedicine.diseasedigestive system diseasesFatty LiverBiomarker EpidemiologyGene Expression RegulationHepatocytesbiology.proteinLiver Neoplasms/etiology/genetics/metabolism/pathologySteatosisbusinessBiomarkersGeneral Pathology
researchProduct

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (E…

2015

Summary Background Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection. Methods Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that…

MalePhases of clinical researchHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundMedicinePharmacology (medical)ChronicAlisporivirAdolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young AdultGastroenterologyHepatitis CRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeCombinationCyclosporineDrug Therapy CombinationFemaleHumanUnited StateAdultmedicine.medical_specialtyAdolescentGenotypeAlpha interferonPlaceboAntiviral AgentsYoung AdultDrug TherapyDouble-Blind MethodInternal medicineRibavirinHumansAdverse effectAgedAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseUnited StatesRegimenchemistryImmunologybusinessAlimentary pharmacologytherapeutics
researchProduct

Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes.

2014

Aims Although there is still no clear definition of “adipose tissue dysfunction” or ATD, the identification of a clinical marker of altered fat distribution and function may provide the needed tools for early identification of a condition of cardiometabolic risk. Our aim was to evaluate the correlations among various anthropometric indices [BMI, Waist Circumference (WC), Hip Circumference (HC), Waist/Hip ratio (WHR), Body Adiposity Index (BAI) and Visceral adiposity Index (VAI)] and several adipocytokines [Visfatin, Resistin, Leptin, Soluble leptin receptors (sOB-R), Adiponectin, Ghrelin, Adipsin, PAI-1, vascular endothelial growth factor (VEGF), Hepatocyte growth factor (HGF) TNF-α, hs-CRP…

MalePhysiologyEpidemiologylcsh:MedicineType 2 diabetesSettore MED/13 - EndocrinologiaEndocrinologyImmune PhysiologyMedicine and Health SciencesCluster AnalysisClinical Epidemiologylcsh:ScienceAdiposityMultidisciplinaryAnthropometryLeptinVAI adipokine diabetesMiddle AgedLipidsType 2 DiabetesPhysiological ParametersResearch DesignCytokinesFemaleAnatomyResearch Articlemedicine.medical_specialtyWaistClinical Research DesignImmunologyAdipokineEndocrine SystemIntra-Abdominal FatBody adiposity indexResearch and Analysis MethodsAdipokinesInternal medicineDiabetes MellitusmedicineHumansObesityAgedNutritionDiabetic EndocrinologyAdiponectinbusiness.industryBody Weightlcsh:RBiology and Life SciencesMolecular Developmentmedicine.diseaseEndocrinologyDiabetes Mellitus Type 2ROC CurveImmune SystemMetabolic DisordersClinical ImmunologyResistinlcsh:QMetabolic syndromebusinessDevelopmental BiologyPLoS ONE
researchProduct

Discover cervical disc arthroplasty versus anterior cervical discectomy and fusion in symptomatic cervical disc diseases: A meta-analysis.

2016

OBJECTIVE:Symptomatic cervical disc disease (SCDD) is a common degenerative disease, and Discover artificial cervical disc, a new-generation nonconstrained artificial disk, has been developed and performed gradually to treat it. We performed this meta-analysis to compare the efficacy and safety between Discover cervical disc arthroplasty (DCDA) and anterior cervical discectomy and fusion (ACDF) for SCDD. METHODS:An exhaustive literature search of PubMed, EMBASE, and the Cochrane Library was conducted to identify randomized controlled trials that compared DCDA with ACDF for patients suffering SCDD. A random-effect model was used. Results were reported as standardized mean difference or risk …

MalePhysiologymedicine.medical_treatmentSensory Physiologylcsh:MedicineAnterior cervical discectomy and fusionIntervertebral Disc DegenerationCochrane LibraryOssificationlaw.invention0302 clinical medicineMathematical and Statistical TechniquesRandomized controlled triallawMedicine and Health SciencesRange of Motion Articularlcsh:ScienceIntervertebral DiscRandomized Controlled Trials as Topic030222 orthopedicsProstheticsMultidisciplinaryMiddle AgedSensory SystemsTreatment OutcomeSomatosensory SystemResearch DesignMeta-analysisPhysical SciencesCervical VertebraeFemaleBone RemodelingRange of motionIntervertebral Disc DisplacementStatistics (Mathematics)DiskectomyResearch ArticleBiotechnologyAdultmedicine.medical_specialtyDrug Research and DevelopmentClinical Research DesignSurgical and Invasive Medical ProceduresResearch and Analysis MethodsArthroplasty03 medical and health sciencesMusculoskeletal System ProceduresmedicineHumansClinical TrialsStatistical MethodsPharmacologybusiness.industrylcsh:RBiology and Life SciencesPain SensationArthroplastyRandomized Controlled TrialsSurgeryAssistive TechnologiesStrictly standardized mean differenceRelative risklcsh:QMedical Devices and EquipmentAdverse EventsClinical MedicinebusinessPhysiological Processes030217 neurology & neurosurgeryMathematicsMeta-AnalysisNeurosciencePloS one
researchProduct

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale

2002

Abstract Introduction: Platinum-based chemotherapy is the gold standard in advanced non-small cell lung cancer (NSCLC), although with relevant toxic effects. Both docetaxel (DCT) and gemcitabine (GEM) have shown activity as single agent in advanced NSCLC with a different toxicity profile and a lack of cross-resistance. Materials and methods: From April 2000 to May 2001, 47 consecutive patients were enrolled in a multicenter phase II trial. Main inclusion criteria included untreated patients with histologically confirmed NSCLC, age⩽70 years, stage IIIB/IV, Eastern Cooperative Oncology Group performance status (PS) 0–2, measurable disease, adequate hematologic, cardiac, hepatic and renal func…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaCost ControlPaclitaxelSurvivalmedicine.medical_treatmentPhases of clinical researchDocetaxelNeutropeniaDeoxycytidineGastroenterologyDrug CostsCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansLung cancerAgedChemotherapybusiness.industryMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessProgressive diseasemedicine.drugLung Cancer
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct

A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer

2013

Background: In vitro data suggest that panobinostat (LBH589), a pan-deacetylase inhibitor, may add therapeutic benefit in the treatment of small-cell lung cancer (SCLC) with regression of tumors. Methods: This multicenter, nonrandomized phase 2 trial was designed to evaluate antitumor activity of LBH589 in patients with previously treated SCLC. Patients received LBH589 administered intravenously at a dose of 20 mg/mq (days 1–8) every 21 days. Results: A total of 21 patients with extensive- or limited-stage SCLC were enrolled. Patients received a median of two cycles (range, 1–6). LBH589 was well tolerated, and the most common toxicities were grade 1 to 2 gastrointestinal disorders (nausea 3…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyIndolesLung Neoplasmsmedicine.drug_classNauseaPhases of clinical researchAntineoplastic AgentsHydroxamic AcidsGastroenterologySmall-cell lung cancerDeacetylase inhibitor.chemistry.chemical_compoundInternal medicinePanobinostatPanobinostatmedicineHumansLung cancerAgedbusiness.industryHistone deacetylase inhibitorMiddle Agedmedicine.diseaseSmall Cell Lung CarcinomaSurgeryHistone Deacetylase InhibitorsLBH58Clinical trialDiarrheaOncologychemistryVomitingFemalePhase II trialmedicine.symptombusinessJournal of Thoracic Oncology
researchProduct

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

2017

Background The risk and outcomes of stroke in patients with chronic obstructive pulmonary disease exacerbations (COPDe) remain unclear. We examined whether patients with COPDe faced increased risk of stroke or post-stroke outcomes. Methods Using Taiwan’s National Health Insurance Research Database, we identified 1918 adults with COPDe and selected comparison cohorts of 3836 adults with COPD no exacerbations and 7672 adults without COPD who were frequency matched by age and sex in 2000–2008 (Study 1). Stroke event was identified during 2000–2013 follow-up period. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of stroke associated with COPDe were calculated. In a nested cohor…

MalePulmonologyEconomicslcsh:MedicineSocial SciencesComorbidityVascular MedicinePulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMedicine and Health SciencesOdds Ratio030212 general & internal medicinelcsh:ScienceStrokeAged 80 and overCOPDMultidisciplinaryHazard ratioMiddle AgedStrokeHospitalizationNeurologyResearch DesignPopulation SurveillanceDisease ProgressionFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignChronic Obstructive Pulmonary DiseaseCerebrovascular DiseasesCardiologyTaiwanResearch and Analysis MethodsRisk Assessment03 medical and health sciencesHealth EconomicsInternal medicinemedicineHumansIntensive care medicineAdverse effectIschemic StrokeAgedRetrospective StudiesEpilepsybusiness.industrylcsh:RRetrospective cohort studyOdds ratioPneumoniamedicine.diseaseComorbidityrespiratory tract diseasesHealth CarePatient Outcome Assessment030228 respiratory systemlcsh:QAdverse EventsbusinessHealth InsurancePLoS ONE
researchProduct